A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.
Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
-
University of Florida, Division of Cardiovascular Medicine, Gainesville, Florida, United States, 32610
Ascension St. John Hospital, Detroit, Michigan, United States, 48236
Mayo Clinic, Cardiovascular Research, Rochester, Minnesota, United States, 55905
St. Luke's Health System, Cardiovascular Research, Kansas City, Missouri, United States, 64111
Hackensack Meridian Mountainside Medical Center, Montclair, New Jersey, United States, 07042
The Christ Hospital, Cincinnati, Ohio, United States, 45219
Cleveland Clinic, Cardiovascular Medicine Research, Cleveland, Ohio, United States, 44195
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Genetesis Inc.,
Zoe E Swann, PhD, STUDY_DIRECTOR, Genetesis Inc.
2024-12-15